肺腺癌TTF-1阴性:临床病理、基因组、免疫表型特征及免疫治疗与KRASG12C抑制剂疗效
研究纳入3297例肺腺癌患者,TTF-1阴性占15%。与TTF-1阳性相比,TTF-1阴性患者吸烟史更常见、PD-L1表达更低,且富集STK11、KEAP1、SMARCA4、NKX2-1、CDKN2A和KRAS突变。TTF-1阴性患者接受免疫检查点抑制剂、化疗联合免疫治疗、度伐利尤单抗巩固治疗及KRASG12C抑制剂的疗效均更差。
要点
- TTF-1阴性肺腺癌约占15%,与吸烟史更常见和PD-L1表达更低相关。
- TTF-1阴性肺腺癌富集STK11、KEAP1、SMARCA4、NKX2-1、CDKN2A和KRAS突变。
- TTF-1阴性提示免疫治疗、化疗联合免疫治疗及KRASG12C抑制剂疗效更差。
核心结论
- TTF-1阴性识别出一组对免疫治疗、化疗联合免疫治疗和KRASG12C抑制剂疗效更差的肺腺癌亚群。
研究设计与样本
- 纳入来自五个机构、癌症基因组图谱、Stand Up To Cancer-Mark Foundation及POPLAR/OAK数据集的具有TTF-1免疫组化结果的肺腺癌患者,共3297例。
主要发现
- TTF-1阴性占15%(n=496),TTF-1阳性占85%(n=2801);TTF-1阴性者吸烟史更常见且PD-L1表达更低。
- TTF-1阴性肺腺癌富集STK11、KEAP1、SMARCA4、NKX2-1、CDKN2A和KRAS突变(q < 0.05)。
- 转移性TTF-1阴性肺腺癌接受免疫检查点抑制剂(n=233)对比TTF-1阳性(n=1179):ORR 17% vs 28%(p=0.001),mPFS 2.5 vs 4.4个月(p < 0.0001),mOS 9.6 vs 20.2个月(p < 0.0001)。
- TTF-1阴性对比TTF-1阳性接受化疗联合免疫治疗:ORR 26% vs 41%(p < 0.0001),mPFS 4.6 vs 8.2个月(p < 0.0001),mOS 11.2 vs 23.4个月(p < 0.0001)。
- 不可切除III期接受放化疗后度伐利尤单抗:TTF-1阴性对比阳性mPFS 8.0 vs 24.8个月(p=0.016),mOS 20.0个月 vs 未达到(p=0.004);KRASG12C突变肺腺癌接受KRASG12C抑制剂:ORR 13% vs 36%(p=0.03),mPFS 2.7 vs 5.9个月(p < 0.0001),mOS 4.4 vs 12.1个月(p < 0.0001)。
临床怎么用
- TTF-1免疫组化结果可用于提示肺腺癌患者对免疫治疗、化疗联合免疫治疗及KRASG12C抑制剂的疗效可能更差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Thyroid transcription factor-1 (TTF-1) expression, routinely assessed through immunohistochemistry in the diagnostic evaluation of lung adenocarcinomas (LUADs), is negative (TTF-1Neg) in approximately 15% to 20% of cases. Although worse outcomes have been reported for these tumors compared with TTF-1-positive (TTF-1Pos) LUAD, a comprehensive characterization of TTF-1 negativity is currently lacking. METHODS: Patients with LUAD and available TTF-1 immunohistochemistry from five institutions, The Cancer Genome Atlas, the Stand Up To Cancer-Mark Foundation, and the POPLAR/OAK data sets, were included. Features and outcomes were analyzed according to TTF-1 expression. RESULTS: Among 3297 patients, TTF-1Neg (15%, n = 496), compared with TTF-1Pos (85%, n = 2801), was associated with a more frequent tobacco use history and lower PD-L1 expression. TTF-1Neg LUAD was enriched for STK11, KEAP1, SMARCA4, NKX2-1, CDKN2A, and KRAS mutations (q < 0.05). Patients with metastatic TTF-1Neg LUAD treated with immune checkpoint inhibitors (n = 233), compared with TTF-1Pos cases (n = 1179), had worse objective response rates (ORR, 17% versus 28%, p = 0.001), median progression-free survival (mPFS, 2.5 versus 4.4 mo, p < 0.0001), and median overall survival (mOS, 9.6 versus 20.2 mo, p < 0.0001). Similarly, TTF-1Neg cases had worse outcomes to chemoimmunotherapy (ORR, 26% versus 41%, p < 0.0001; mPFS, 4.6 versus 8.2 mo, p < 0.0001; mOS, 11.2 versus 23.4 mo, p < 0.0001), durvalumab after chemoradiation for unresectable stage III disease (mPFS, 8.0 versus 24.8 mo, p = 0.016; mOS, 20.0 mo versus not reached, p = 0.004), and KRASG12C inhibitors in KRASG12C-mutant LUAD (ORR, 13% versus 36%, p = 0.03; mPFS, 2.7 versus 5.9 mo, p < 0.0001; mOS, 4.4 versus 12.1 mo, p < 0.0001). CONCLUSIONS: TTF-1 negativity identifies a subset of LUAD with worse outcomes to immunotherapy, chemoimmunotherapy, and KRASG12C inhibitors.
引用
- Di Federico A, Hong L, Elkrief A, et al. TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors. J Thorac Oncol. 2026. PMID: 41690367. doi:10.1016/j.jtho.2026.103610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。